CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Net sales	$ 1,532.2	$ 1,369.4	$ 2,944.9	$ 2,699.3
Cost of sales	344.4	275.5	646.0	562.4
Gross profit	1,187.8	1,093.9	2,298.9	2,136.9
Selling, general, and administrative expenses	502.0	447.5	967.7	875.9
Research and development expenses	276.2	271.8	530.8	528.5
Certain litigation expenses	15.5	8.1	26.4	17.0
Separation costs (Note 3)	4.2	0.0	8.4	0.0
Other operating income	(21.3)	0.0	(40.4)	0.0
Operating income, net	411.2	366.5	806.0	715.5
Interest income, net	(37.4)	(15.5)	(73.9)	(32.0)
Loss on impairment	47.1	0.0	47.1	0.0
Other non-operating expense (income), net	1.3	(2.0)	(1.3)	(7.7)
Income from continuing operations before provision for income taxes	400.2	384.0	834.1	755.2
Provision for income taxes	64.3	20.0	134.6	66.3
Net income from continuing operations	335.9	364.0	699.5	688.9
(Loss) income from discontinued operations, net of tax	(4.4)	1.0	(11.6)	27.1
Net income	331.5	365.0	687.9	716.0
Net loss attributable to noncontrolling interest	(1.7)	(1.3)	(3.3)	(2.2)
Net income attributable to Edwards Lifesciences Corporation	$ 333.2	$ 366.3	$ 691.2	$ 718.2
Basic:
Continuing operations (in dollars per share)	$ 0.58	$ 0.61	$ 1.20	$ 1.15
Discontinued operations (in dollars per share)	(0.01)	0	(0.02)	0.04
Basic earnings per share (in dollars per share)	0.57	0.61	1.18	1.19
Diluted:
Continuing operations (in dollars per share)	0.57	0.61	1.20	1.15
Discontinued operations (in dollars per share)	(0.01)	0	(0.02)	0.04
Diluted earnings per share (in dollars per share)	$ 0.56	$ 0.61	$ 1.18	$ 1.19
Weighted-average number of common shares outstanding:
Basic (in shares)	587.0	602.1	586.9	601.8
Diluted (in shares)	587.9	604.3	587.9	604.2